Allay Therapeutics
PrivateLast Round
Debt
Jun 5, 2025
Total Funding Raised
$200M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Allay Therapeutics operates in Healthcare & Life Sciences and is based in San Jose, California. Its latest recorded funding round was a Debt round in June 2025.
Allay Therapeutics is a biotechnology company that develops ultra-sustained analgesic products aimed at enhancing post-surgical pain management and recovery for patients and healthcare providers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allay Therapeutics Comparables
Compare Allay Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Concentric Analgesics | 88% | |
| Cali Biosciences | 85% | |
| Rebel Medicine | 84% |
For institutional investors. Book with your work email.
Allay Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Jun 5, 2025 | ||||
| Series D | Jun 5, 2025 | ||||
| Debt | Jun 5, 2025 | ||||
| Series C | Sep 15, 2021 | ||||
| Series B | Feb 7, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Allay Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Temasek | Series C |
| Vertex Ventures HC | Debt, Series D, Series C |
| Arboretum Ventures | Debt, Series D, Series C |
| New Enterprise Associates | Debt, Series D, Series C, Series B |
| Lightstone Ventures | Series B, Seed, Debt, Series D, Series A |
| ClavystBio | Debt, Series D |
| EDBI | Debt, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 33% MoM, reaching 2.1K.
- Jun 5, 2025
Secured debt financing led by HSBC Innovation Banking.
For institutional investors. Book with your work email.
Allay Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Allay Therapeutics's valuation, stock price, and market status.
Is Allay Therapeutics a public or private company?
Allay Therapeutics is a private company.
What is the current stock price of Allay Therapeutics?
Allay Therapeutics is a private company, so its shares have no public market price. Caplight tracks Allay Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allay Therapeutics worth (valuation)?
Valuation information for Allay Therapeutics is not publicly available.
Can I buy Allay Therapeutics stock?
Allay Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allay Therapeutics's last funding round?
Allay Therapeutics's most recent funding round was Debt on June 5, 2025.
Who are the main investors in Allay Therapeutics?
Key investors in Allay Therapeutics include Arboretum Ventures, New Enterprise Associates, Lightstone Ventures, ClavystBio, HSBC Innovation Banking.
Will Allay Therapeutics IPO soon?
No public IPO plans have been announced for Allay Therapeutics.
How can I track Allay Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Allay Therapeutics's shares on secondary markets.